Lung Cancer

Improving outcomes for patients with non– small cell lung cancer (NSCLC) is particularly relevant because NSCLC accounts for 85% of all cases of lung cancer.

Significant advances in treating non–small cell lung cancer (NSCLC) have been made over the past 10 years; nevertheless, survival im provement in this disease pales compared with many other solid tumors. Because maintenance chemotherapy offers improved survival in NSCLC, patients and doctors are justifiably excited.